FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950580054> ?p ?o ?g. }

• W2950580054 abstract "Purpose: The oligometastatic state is a proposed entity between localized cancer and widely metastatic disease, comprising an intermediate subset of metastatic cancer patients. Most data to support locally-directed treatment, such as stereotactic ablative radiotherapy (SABR), for oligometastases are from retrospective institutional reports. Following the success of a recently completed and reported phase II trial demonstrating important clinical outcomes, herein we review the current landscape of ongoing clinical trials in this context. Materials and methods: A review of currently activated and registered clinical trials was performed using the clinicaltrials.gov database from inception to February 2019. A search of actively recruiting trials, using the key words oligometastases, SABR, and various related terms was performed. Search results were independently reviewed by 2 investigators, with discrepancies settled by a third. Data abstracted from identified studies included study type, primary disease site, oncologic endpoints, and inclusion/exclusion criteria. Results: Of the initial 216 entries identified, 64 met our review eligibility criteria after full-text review. The most common study type was a Phase II clinical trial (n=35, 55%) with other study designs ranging from observational registry trials to Phase III randomized controlled trials. A minority of trials were randomized in design (n=17, 27%). While most studies allowed for metastases from multiple primary disease sites (n=22, 34%), the most common was prostate (n=13, 15%), followed by breast, gastrointestinal, non-small cell lung cancer and renal (n=6, 9% each). In studies with a solitary target site, the most common was liver (n=6, 9%) followed by lung (n=3, 5%). The most common primary endpoints were progression-free survival (n=20, 31%) and toxicity (n=10, 16%). A combined strategy of systemic therapy and SABR was an emerging theme (n=23, 36%), with more recent studies specifically evaluating SABR and immunotherapy (n=9, 14%). Conclusion: The safety and efficacy of SABR as oligometastasis-directed treatment is increasingly being evaluated within prospective clinical trials. These data are awaited to compliment the abundance of existing observational studies and to guide clinical decision-making." @default.
• W2950580054 created "2019-06-27" @default.
• W2950580054 creator A5012664209 @default.
• W2950580054 creator A5032441898 @default.
• W2950580054 creator A5038486476 @default.
• W2950580054 creator A5047391244 @default.
• W2950580054 creator A5090288280 @default.
• W2950580054 date "2019-06-21" @default.
• W2950580054 modified "2023-10-13" @default.
• W2950580054 title "A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead?" @default.
• W2950580054 cites W1891507428 @default.
• W2950580054 cites W2030505692 @default.
• W2950580054 cites W2031688279 @default.
• W2950580054 cites W2049969953 @default.
• W2950580054 cites W2058188403 @default.
• W2950580054 cites W2059812828 @default.
• W2950580054 cites W2085070000 @default.
• W2950580054 cites W2114932214 @default.
• W2950580054 cites W2125800083 @default.
• W2950580054 cites W2168325971 @default.
• W2950580054 cites W2186638557 @default.
• W2950580054 cites W2403758065 @default.
• W2950580054 cites W2498309700 @default.
• W2950580054 cites W2536769127 @default.
• W2950580054 cites W2594293825 @default.
• W2950580054 cites W2618641368 @default.
• W2950580054 cites W2761351587 @default.
• W2950580054 cites W2775321189 @default.
• W2950580054 cites W2785665594 @default.
• W2950580054 cites W2787553571 @default.
• W2950580054 cites W2796600021 @default.
• W2950580054 cites W2802715402 @default.
• W2950580054 cites W2890639244 @default.
• W2950580054 cites W2913109127 @default.
• W2950580054 cites W2939770857 @default.
• W2950580054 cites W3080889076 @default.
• W2950580054 doi "https://doi.org/10.3389/fonc.2019.00543" @default.
• W2950580054 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6598429" @default.
• W2950580054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31293976" @default.
• W2950580054 hasPublicationYear "2019" @default.
• W2950580054 type Work @default.
• W2950580054 sameAs 2950580054 @default.
• W2950580054 citedByCount "48" @default.
• W2950580054 countsByYear W29505800542019 @default.
• W2950580054 countsByYear W29505800542020 @default.
• W2950580054 countsByYear W29505800542021 @default.
• W2950580054 countsByYear W29505800542022 @default.
• W2950580054 countsByYear W29505800542023 @default.
• W2950580054 crossrefType "journal-article" @default.
• W2950580054 hasAuthorship W2950580054A5012664209 @default.
• W2950580054 hasAuthorship W2950580054A5032441898 @default.
• W2950580054 hasAuthorship W2950580054A5038486476 @default.
• W2950580054 hasAuthorship W2950580054A5047391244 @default.
• W2950580054 hasAuthorship W2950580054A5090288280 @default.
• W2950580054 hasBestOaLocation W29505800541 @default.
• W2950580054 hasConcept C106159729 @default.
• W2950580054 hasConcept C121608353 @default.
• W2950580054 hasConcept C126322002 @default.
• W2950580054 hasConcept C143998085 @default.
• W2950580054 hasConcept C151730666 @default.
• W2950580054 hasConcept C162324750 @default.
• W2950580054 hasConcept C168563851 @default.
• W2950580054 hasConcept C187625094 @default.
• W2950580054 hasConcept C19617505 @default.
• W2950580054 hasConcept C2779134260 @default.
• W2950580054 hasConcept C2779343474 @default.
• W2950580054 hasConcept C2780192828 @default.
• W2950580054 hasConcept C2780387249 @default.
• W2950580054 hasConcept C509974204 @default.
• W2950580054 hasConcept C530470458 @default.
• W2950580054 hasConcept C535046627 @default.
• W2950580054 hasConcept C71924100 @default.
• W2950580054 hasConcept C85393063 @default.
• W2950580054 hasConcept C86803240 @default.
• W2950580054 hasConcept C91602232 @default.
• W2950580054 hasConceptScore W2950580054C106159729 @default.
• W2950580054 hasConceptScore W2950580054C121608353 @default.
• W2950580054 hasConceptScore W2950580054C126322002 @default.
• W2950580054 hasConceptScore W2950580054C143998085 @default.
• W2950580054 hasConceptScore W2950580054C151730666 @default.
• W2950580054 hasConceptScore W2950580054C162324750 @default.
• W2950580054 hasConceptScore W2950580054C168563851 @default.
• W2950580054 hasConceptScore W2950580054C187625094 @default.
• W2950580054 hasConceptScore W2950580054C19617505 @default.
• W2950580054 hasConceptScore W2950580054C2779134260 @default.
• W2950580054 hasConceptScore W2950580054C2779343474 @default.
• W2950580054 hasConceptScore W2950580054C2780192828 @default.
• W2950580054 hasConceptScore W2950580054C2780387249 @default.
• W2950580054 hasConceptScore W2950580054C509974204 @default.
• W2950580054 hasConceptScore W2950580054C530470458 @default.
• W2950580054 hasConceptScore W2950580054C535046627 @default.
• W2950580054 hasConceptScore W2950580054C71924100 @default.
• W2950580054 hasConceptScore W2950580054C85393063 @default.
• W2950580054 hasConceptScore W2950580054C86803240 @default.
• W2950580054 hasConceptScore W2950580054C91602232 @default.
• W2950580054 hasLocation W29505800541 @default.
• W2950580054 hasLocation W29505800542 @default.
• W2950580054 hasLocation W29505800543 @default.
• W2950580054 hasLocation W29505800544 @default.
• W2950580054 hasOpenAccess W2950580054 @default.

• next